# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst David Turkaly reiterates Haemonetics (NYSE:HAE) with a Market Outperform and maintains $125 price tar...
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target f...
Haemonetics (NYSE:HAE) reported quarterly earnings of $1.02 per share which beat the analyst consensus estimate of $1.00 by 2 p...
The SavvyWire guidewire is the world's first and only sensor-guided 3-in-1 solution for Transcatheter Aortic Valve Implanta...
Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY26 through product mix anal...
Needham analyst Mike Matson upgrades Haemonetics (NYSE:HAE) from Hold to Buy and announces $112 price target.